Aetna · Iort · US health-plan appeal rights

Iort denied as duplicate or overlapping therapy by Aetna?

Q: How long do I have to appeal a Aetna Iort denial?

Internal appeal window: Typically 180 days from the denial date. External review window: Typically 60–120 days after the final internal denial. The clock starts from the date on the denial letter.

If two medications appear duplicative on paper but serve different clinical purposes (e.g., short-acting vs long-acting), the appeal needs to spell out the clinical rationale for both.

By Michael John Ryan, Founder & Privacy Officer, DenialHelp, LLC

Last reviewed 2026-05-09

Policy data current as of 2026-05-01

US health-plan appeal rights

Cite: Most US health plans have appeal rights under either the ACA, ERISA, or Medicare/Medicaid rules

Most US health plans are required by federal law to give you both an internal appeal (where the insurer reconsiders) and an external review (where an independent reviewer decides). The exact timelines and processes depend on what kind of plan you have — marketplace / employer group, self-funded, Medicare Advantage, or Medicaid MCO — but in every case there's a window after the denial during which you have the right to fight it.

Internal appeal window

Typically 180 days from the denial date

External review window

Typically 60–120 days after the final internal denial

What Aetna typically requires

Aetna considers IORT medically necessary for select early-stage breast cancer patients meeting TARGIT-A inclusion criteria: age ≥50, unifocal invasive ductal carcinoma, T1 (≤2cm), node-negative, hormone-receptor positive, HER2-negative, no extensive intraductal component. IORT may be delivered as single-fraction at lumpectomy (boost) or as primary partial-breast irradiation. Aetna considers IORT investigational/experimental for most non-breast indications (rectal, glioblastoma, sarcoma, recurrent rectal/pelvic) absent specific guideline support.

Source policy: Aetna CPB 0721 — Intraoperative Radiation Therapy (IORT) — read the policy

What works in the appeal

TARGIT-A 5-yr long-term (Vaidya BMJ 2020;370:m2836) — non-inferior local control vs WBRT for selected patients meeting TARGIT-A criteria, sustained at 12-yr follow-up (Vaidya 2024). ELIOT 5-yr + 10-yr (Veronesi Lancet Oncol 2013;14:1269; Orecchia 2021) — Italian electron IORT outcomes for selected low-risk profile. GEC-ESTRO consensus on partial-breast irradiation 2010/2024 update (Strnad). ASTRO APBI Consensus Statement 2017/update — IORT category eligibility table. NCCN Breast Cancer v2.2024 lists IORT as APBI option meeting selection criteria. For rectal IORT cite NCCN Rectal Cancer v3.2024 (locally advanced + R0 close margin) and Calvo et al EJC 2014 IORT outcomes. Document staging completion (sentinel node, IHC), final pathology with margins, multidisciplinary tumor board recommendation. Submit ABS / ASTRO / ASCO position statements where applicable.

The Aetna angle on Iort

## Why Aetna Denies Intraoperative Radiation Therapy as Duplicate Therapy — and How to Appeal

A duplicate-therapy denial for Intraoperative Radiation Therapy (IORT) means Aetna has determined that whole-breast or external-beam radiation therapy already approved or rendered for the same course of treatment makes IORT redundant. This denial pattern arises most often in breast cancer cases where IORT is used as a tumor-bed boost or as a partial-breast irradiation technique during lumpectomy. The key to overturning it is demonstrating that IORT and any other radiation modality serve clinically distinct purposes and are not interchangeable.

## Why This Denial Is Appealable

IORT delivers a precisely targeted, single-fraction dose directly to the tumor bed at the time of surgery, with a distinct clinical rationale from conventionally fractionated external-beam whole-breast irradiation. When the oncology team has documented a specific clinical indication for IORT — such as reducing radiation scatter to adjacent structures, accommodating patient comorbidities, or serving as the definitive partial-breast irradiation — the two modalities are not duplicative. Aetna's clinical criteria for IORT should enumerate the conditions under which it is covered; if your case meets those conditions, the duplicate-therapy characterization is factually incorrect.

## Federal Appeal Framework

Internal appeal: Under ERISA §503 or state law, you have the right to a full-and-fair review. File within the timeframe on the denial notice. Request the specific policy provision Aetna relied on to characterize IORT as duplicative.
External review: After exhausting internal appeals, escalate to an independent IRO under ACA §2719, generally within four months of the final adverse determination.
Expedited review: If the denial delays a scheduled surgical procedure, expedited review is appropriate — decisions are typically required within 72 hours.

## Documentation to Gather

Diagnosis and staging: Pathology report, tumor size, receptor status, and surgical plan confirming the clinical context.
Radiation oncology treatment plan: The radiation oncologist's written plan explaining why IORT is the selected modality, the clinical rationale, and how it differs from any other radiation treatment in the plan of care.
Distinct-purpose letter: A letter from the treating radiation oncologist stating explicitly that IORT is not duplicative of any approved external-beam treatment and explaining the clinical distinction.
Operative report or surgical plan: Documentation tying IORT to the surgical procedure and confirming it cannot be separated into a standalone course of treatment.
Applicable guideline support: Reference to the relevant professional organization's guidance (such as the applicable ASTRO or NCCN guideline) supporting IORT in the patient's clinical scenario.

## Criteria-Mapping Structure

Retrieve Aetna's published IORT coverage policy. Identify every condition under which IORT is covered and every condition under which it is excluded as duplicative. Map each criterion to a specific chart finding or document. If the denial letter does not specify which duplicate-therapy provision applies, demand that clarification in writing as part of the appeal — Aetna is required under ERISA to provide the specific reason and the plan provision on which it is based.

Next steps

Find the date on the denial letter — your appeal window starts there.
Read your plan's Summary of Benefits and Coverage (SBC) for the specific deadlines.
Request the insurer's claim file in writing — they must provide it.
Submit your appeal in writing with new clinical evidence and a physician statement.

Get the letter drafted

DenialHelp drafts your appeal in 5 minutes — $40 list price, $30 for your first letter (use code SEO25). We cite the federal regs and the specific clinical evidence your plan responds to. Your physician signs and sends.

Start my appeal — $30 with code SEO25 →

Related appeal guides

Other Aetna appeals

Other denial reasons for Aetna Iort

denied as not medically necessary denied for failing step therapy denied as non-formulary denied for missing prior authorization denied as experimental or investigational

This guide describes general US federal appeal rights based on Most US health plans have appeal rights under either the ACA, ERISA, or Medicare/Medicaid rules. Your specific plan documents (Summary of Benefits and Coverage, Evidence of Coverage) override anything here. DenialHelp is not your lawyer and not your physician — we draft appeal letters that your physician signs. Outcomes depend on your insurer's decision and factors outside our control. Reviewed by Michael John Ryan on 2026-05-09. Editorial standards: denialhelp.com/authors.